Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Acolbifene

Known as: (2S)-3-(4-Hydroxyphenyl)-4-methyl-2-(4-(2-(1-piperidinyl)ethoxy)phenyl)-2H-1-benzopyran-7-ol 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2006
Review
2006
The estrogen receptor alpha (ERalpha) has proven to be the single most important target in breast cancer over the last 30 years… Expand
Is this relevant?
2006
2006
PURPOSE We tested whether a selective estrogen receptor modulator (SERM) and a rexinoid are active for prevention and treatment… Expand
Is this relevant?
2006
2006
Tamoxifen is currently used as adjuvant therapy for estrogen receptor (ER) positive breast cancer patients and as a… Expand
Is this relevant?
Review
2006
Review
2006
Menopause, regardless of age at onset, is associated with a marked increase in coronary heart disease (CHD) risk. On the basis of… Expand
Is this relevant?
2005
2005
To assess the specific estrogenic and/or androgenic effects of a potential novel hormone replacement therapy, we have examined… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 5
Is this relevant?
2005
2005
OBJECTIVE:The selective estrogen receptor (ER) modulator (SERM) acolbifene (ACOL), a potent and pure antiestrogen in the mammary… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
2005
2005
This study aimed to identify the mechanisms of the hypolipidemic action of the selective estrogen receptor modulator (SERM… Expand
  • table 1
  • table 2
  • figure 1
  • figure 3
  • figure 2
Is this relevant?
2005
2005
Although approved for the treatment of hormone-dependent breast cancer as well as for the prevention of breast cancer in high… Expand
  • figure 1
  • figure 2
  • figure 4
  • figure 3
  • figure 5
Is this relevant?
2004
2004
PURPOSE To determine the efficacy and safety of EM-800 (SCH-57050), the precursor of acolbifene, a new, highly potent, orally… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2002
2002
Cardiovascular disease is the leading cause of morbidity and mortality in postmenopausal women. EM-652 (acolbifene) is a fourth… Expand
Is this relevant?